biostudies-literatureUnknown17(1)Ding ZEddingpharm Co., Ltd., ChinaShionogi<h4>Purpose</h4>Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10⁹/L) patients undergoing elective invasive procedures.<h4>Methods</h4>In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 10⁹/L that increased to ≥ 20 × 10⁹/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 10⁹/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were alsoHepatology international180-189https://www.ebi.ac.uk/biostudies/studies/S-EPMC9895009biostudies-literatureLusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.PMC9895009Fu XZeng YMeng ZKano TWu HPan HYang WFan JKuang MShi GChen YZou SLiu CWang XDing ZSun HLin KHao CChen RYang SLiang RZhou JfalseLusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.<h4>Purpose</h4>Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10⁹/L) patients undergoing elective invasive procedures.<h4>Methods</h4>In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 10⁹/L that increased to ≥ 20 × 10⁹/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 10⁹/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were also2023-01-01T00:00:00Z2023 Feb2025-04-26T18:09:22.206Z2025-02-19T03:30:30.863ZS-EPMC98950093625806510.1007/s12072-022-10421-9